The discovery of potent, orally bioavailable pyrazolo and triazolopyrimidine CXCR2 receptor antagonists

被引：21

作者：

Porter, David W. ^{[1
]}

Bradley, Michelle ^{[1
]}

Brown, Zarin ^{[1
]}

Canova, Riccardo ^{[2
]}

Charlton, Steven ^{[1
]}

Cox, Brian ^{[1
]}

Hunt, Peter ^{[1
]}

Kolarik, David ^{[2
]}

Lewis, Sarah ^{[1
]}

O'Connor, Des ^{[1
]}

Reilly, John ^{[1
]}

Spanka, Carsten ^{[2
]}

Tedaldi, Lauren ^{[1
]}

Watson, Simon J. ^{[1
]}

Wermuth, Roland ^{[2
]}

Press, Neil J. ^{[1
]}

机构：

[1] Novartis Inst BioMed Res, Horsham Res Ctr, Horsham RH12 5AB, W Sussex, England

[2] Novartis Inst BioMed Res, CH-4056 Basel, Switzerland

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2014年 / 24卷 / 01期

关键词：

CXCR2; Chemokines; Pyrazolopyrimidine; Triazolopyrimidine; Neutrophils; COPD; HIT-TO-LEAD; PULMONARY-DISEASE; INTERLEUKIN-8;

D O I：

10.1016/j.bmcl.2013.11.074

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A hit-to-lead optimisation programme was carried out on the Novartis archive screening hit, pyrazolopyrimidine 2-methyl-5-((phenylthio)methyl)pyrazolo[1,5-a]pyrimidin-7-ol 1, resulting in the discovery of CXCR2 receptor antagonist 2-benzyl-5-(((2,3-difluorophenyl)thio)methyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 14. The SAR was investigated by systematic variation of the pendant thiol, alkyl and pyrimidinol groups. Replacement of the pyrazolopyrimidine core with a triazolo alternative led to a dual series of antagonists with favourable biological and pharmacokinetic properties. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：72 / 76

页数：5

共 50 条

[41] Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathway
Alper, Phil B.
Deane, Jonathan
Betschart, Claudia
Buffet, David
Zipfel, Geraldine Collignon
Gordon, Perry
Hampton, Janice
Hawtin, Stuart
Ibanez, Maureen
Jiang, Tao
Junt, Tobias
Knoepfel, Thomas
Liu, Bo
Maginnis, Jillian
McKeever, Una
Michellys, Pierre-Yves
Mutnick, Daniel
Nayak, Bishnu
Niwa, Satoru
Richmond, Wendy
Rush, James S.
Syka, Peter
Zhang, Yi
Zhu, Xuefeng
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (17)
[42] The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine
Lin, Peter
Chang, Lehua
DeVita, Robert J.
Young, Jonathan R.
Eid, Ronsar
Tong, Xinchun
Zheng, Song
Ball, Richard G.
Tsou, Nancy N.
Chicchi, Gary G.
Kurtz, Marc M.
Tsao, Kwel-Lan C.
Wheeldon, Alan
Carlson, Emma J.
Eng, WaiSi
Burns, H. Donald
Hargreaves, Richard J.
Mills, Sander G.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (18) : 5191 - 5198
[43] Nonpeptide orally bioavailable glucagon receptor antagonists
Kodra, Janos T.
Jorgensen, Anker Steen
Andersen, Birgitte
Behrens, Carsten
Brand, Christian Lehn
Christensen, Inge Thoger
Guldbrandt, Mette
Jeppesen, Claus Bekker
Knudsen, Lotte B.
Madsen, Peter
Nishimura, Erica
Sams, Christian K.
Sidelmann, Ulla G.
Lau, Jesper
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
[44] Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases
Crosignani, Stefano
Page, Patrick
Missotten, Marc
Colovray, Veronique
Cleva, Christophe
Arrighi, Jean-Francois
Atherall, John
Macritchie, Jackie
Martin, Thierry
Humbert, Yves
Gaudet, Marilene
Pupowicz, Doris
Maio, Maurizio
Pittet, Pierre-Andre
Golzio, Lucia
Giachetti, Claudio
Rocha, Cynthia
Bernardinelli, Gerald
Filinchuk, Yaroslav
Scheer, Alexander
Schwarz, Matthias K.
Chollet, Andre
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (07) : 2227 - 2243
[45] Discovery of Potent, Selective, and Orally Bioavailable Alkynylphenoxyacetic Acid CRTH2 (DP2) Receptor Antagonists for the Treatment of Allergic Inflammatory Diseases
Crosignani, Stefano
Pretre, Adeline
Jorand-Lebrun, Catherine
Fraboulet, Gaele
Seenisamy, Jeyaprakashnarayanan
Augustine, John Kallikat
Missotten, Marc
Humbert, Yves
Cleva, Christophe
Abla, Nada
Daff, Hamina
Schott, Olivier
Schneider, Manfred
Burgat-Charvillon, Fabienne
Rivron, Delphine
Hamernig, Ingrid
Arrighi, Jean-Francois
Gaudet, Marilene
Zimmerli, Simone C.
Juillard, Pierre
Johnson, Zoe
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (20) : 7299 - 7317
[46] Discovery of Potent and Orally Bioavailable Macrocyclic Peptide-Peptoid Hybrid CXCR7 Modulators
Boehm, Markus
Beaumont, Kevin
Jones, Rhys
Kalgutkar, Amit S.
Zhang, Liying
Atkinson, Karen
Bai, Guoyun
Brown, Janice A.
Eng, Heather
Goetz, Gilles H.
Holder, Brian R.
Khunte, Bhagyashree
Lazzaro, Sarah
Limberakis, Chris
Ryu, Sangwoo
Shapiro, Michael J.
Tylaska, Laurie
Yan, Jiangli
Turner, Rushia
Leung, Siegfried S. F.
Ramaseshan, Mahesh
Price, David A.
Liras, Spiros
Jacobson, Matthew P.
Earp, David J.
Lokey, R. Scott
Mathiowetz, Alan M.
Menhaji-Klotz, Elnaz
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (23) : 9653 - 9663
[47] Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus
Fader, Lee
Brault, Martine
Desjardins, Jessica
Dansereau, Nathalie
Lamorte, Louie
Tremblay, Sonia
Bilodeau, Francois
Bordeleau, Josee
Duplessis, Martin
Gorys, Vida
Gillard, James
Gleason, James L.
James, Clint
Joly, Marc-Andre
Kuhn, Cyrille
Llinas-Brunet, Montse
Luo, Laibin
Morency, Louis
Morin, Sebastien
Parisien, Mathieu
Poirier, Maude
Thibeault, Carl
Thao Trinh
Sturino, Claudio
Srivastava, Sanjay
Yoakim, Christiane
Franti, Michael
ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (05): : 525 - 530
[48] Discovery of potent and orally bioavailable macrocyclic peptide-peptoid hybrid CXCR7 modulators
不详
CHIMICA OGGI-CHEMISTRY TODAY, 2018, 36 (02) : 28 - 29
[49] Discovery of potent and orally bioavailable macrocyclic peptide-peptoid hybrid CXCR7 modulators
Boehm, Markus
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 255
[50] Discovery of potent and orally bioavailable macrocyclic FXIa inhibitors
Yang, Wu
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254

← 1 2 3 4 5 →